1
|
Yan CQ, Zhao YP, Dai MH, et al: The
relationship between the changes of proangiogenic factors serum
concentrations and progression of pancreatic carcinoma patients.
Zhonghua Wai Ke Za Zhi. 45:496–498. 2007.(In Chinese).
|
2
|
Dai MH, Yan CQ, Zhao YP and Song YM:
Relationship between changes of serum concentrations of
antiangiogenic factors and disease progression in patients of
pancreatic carcinoma. Zhonghua Wai Ke Za Zhi. 45:1199–1201.
2007.(In Chinese).
|
3
|
Yan CQ and Zhao YP: Expression of
angiogenic factors in pancreatic carcinoma cell and their
significance. Zhonghua Wai Ke Za Zhi. 47:787–790. 2009.(In
Chinese).
|
4
|
Yan CQ and Zhao YP: The significance of
VEGF siRNA and bFGF siRNA in invasion and proliferation of
pancreatic carcinoma cell. Zhonghua Wai Ke Za Zhi. 48:610–614.
2010.(In Chinese).
|
5
|
Sakurai T and Kudo M: Signaling pathways
governing tumor angiogenesis. Oncology. 81(Suppl 1): 24–29. 2011.
View Article : Google Scholar
|
6
|
Ohlund D, Ardnor B, Oman M, et al:
Expression pattern and circulating levels of endostatin in patients
with pancreas cancer. Int J Cancer. 122:2805–2810. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wigmore SJ: Endostatin in the pancreas. Br
J Cancer. 92:5–6. 2005. View Article : Google Scholar
|
8
|
Rahbari NN, Schmidt T, Falk CS, et al:
Expression and prognostic value of circulating angiogenic cytokines
in pancreatic cancer. BMC Cancer. 11:2862011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Eichholz A, Merchant S and Gaya AM:
Anti-angiogenesis therapies: their potential in cancer management.
Onco Targets Ther. 3:69–82. 2010.PubMed/NCBI
|
11
|
Korc M: Pathways for aberrant angiogenesis
in pancreatic cancer. Mol Cancer. 2:82003. View Article : Google Scholar
|
12
|
Benckert C, Thelen A, Cramer T, et al:
Impact of microvessel density on lymph node metastasis and survival
after curative resection of pancreatic cancer. Surg Today.
42:169–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Brammer RD, Bramhall SR and Eggo MC:
Endostatin expression in a pancreatic cell line is modulated by a
TNFalpha-dependent elastase. Br J Cancer. 93:1024–1028. 2005.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Heljasvaara R, Nyberg P, Luostarinen J, et
al: Generation of biologically active endostatin fragments from
human collagen XVIII by distinct matrix metalloproteases. Exp Cell
Res. 307:292–304. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Nilsson UW, Garvin S and Dabrosin C: MMP-2
and MMP-9 activity is regulated by estradiol and tamoxifen in
cultured human breast cancer cells. Breast Cancer Res Treat.
102:253–261. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhong J, Gencay MM, Bubendorf L, et al:
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action
and affect cell migration: a comparison between mesothelioma and
mesothelial cells. J Cell Physiol. 207:540–552. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Xie L, Duncan MB, Pahler J, et al:
Counterbalancing angiogenic regulatory factors control the rate of
cancer progression and survival in a stage-specific manner. Proc
Natl Acad Sci USA. 108:9939–9944. 2011. View Article : Google Scholar
|
18
|
Albrecht I, Kopfstein L, Strittmatter K,
et al: Suppressive effects of vascular endothelial growth factor-B
on tumor growth in a mouse model of pancreatic neuroendocrine
tumorigenesis. PLoS One. 5:e141092010. View Article : Google Scholar
|
19
|
Pereira ER, Liao N, Neale GA and
Hendershot LM: Transcriptional and post-transcriptional regulation
of proangiogenic factors by the unfolded protein response. PLoS
One. 5:e125212010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Schuch G, Kisker O, Atala A and Soker S:
Pancreatic tumor growth is regulated by the balance between
positive and negative modulators of angiogenesis. Angiogenesis.
5:181–190. 2002. View Article : Google Scholar : PubMed/NCBI
|